Introduction Glucagon as an Anti-Obesity Agent Obesity is a leading cause of global morbidity and death
Effects of acute and repeated treatment with the biased -opioid receptor agonist TRV130 (oliceridine) on measures of antinociception, gastrointestinal function, and abuse liability in rodents
Berry CE, Kendig CB, An N et al (2024) Role of ferroptosis in radiation-induced soft tissue injury
The ability of GLP-1 receptor agonists to reduce food cravings and quiet food noise appears to stem from their effects on brain reward circuitry
Conclusion Optimal retatrutide dosage selection is both a science and an art requiring integration of pharmacokinetic principles, clinical evidence, species-specific considerations, and individual patient or model characteristics
GLP-1 drugs for heart health Trulicity (dulaglutide) was approved in 2020 for individuals with type 2 diabetes, with or without a history of heart disease, to help reduce the risk of serious cardiovascular events, like heart attacks